Amundi
AXSM icon

Amundi’s Axsome Therapeutics AXSM Stock Holding History

Amundi’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$851K Buy
3,477
+532
+18% +$115K ﹤0.01% 1444
2026
Q1 		$498K Buy
+2,945
New +$509K ﹤0.01% 1548
2022
Q4 		– Sell
-3,053
Closed -$141K – 1902
2022
Q3 		$141K Hold
3,053
– – ﹤0.01% 1503
2022
Q2 		$135K Buy
+3,053
New +$96.6K ﹤0.01% 1404
2021
Q3 		– Sell
-2,800
Closed -$189K – 1568
2021
Q2 		$189K Buy
+2,800
New +$168K ﹤0.01% 1387

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Amundi's AXSM Position: Q2 2026 in Review

Amundi increased its Axsome Therapeutics (AXSM) stake by 18% in Q2 2026, buying an estimated $115K and bringing the position to 3,477 shares worth $851K. The position accounts for ﹤0.01% of the portfolio, ranked #1444.

Amundi first reported a position in AXSM in Q2 2021 and has held it in 5 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Amundi held 3,477 shares of Axsome Therapeutics worth $851K as of Q2 2026.
  • Amundi bought 532 Axsome Therapeutics shares in Q2 2026, an estimated $115K.
  • Axsome Therapeutics made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1444 holding.
  • Amundi first reported a position in Axsome Therapeutics in Q2 2021 and has held it in 5 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.